|
@ thebull weißt Du den Kurs von prcs von Freitag nachbörslich auf island ??? die news war schon Freitag um 16.21 Uhr in amiland bekannt siehe Posting : THOUSAND OAKS, Calif. (CBS.MW) - Shares of Amgen rose about seven percent Friday, despite a first-quarter profit report that warned of slowing growth and a delay in marketing approval for some key products. Late Thursday the biotech firm (AMGN: news, msgs, alerts) said net income rose to $305 million, or 28 cents a share, up from $266.2 million, or 25 cents a share in the same quarter a year ago. Revenue rose to $901.6 million from $814.1 million. Results were a penny a share ahead of the average estimate of 22 analysts in a First Call/Thomson Financial survey. Shares fell in after-hours trading, but were up a healthy 7.1 percent to $59.88 on Friday. Nonetheless, Amgen stock has been falling steadily since February. Even with Friday`s gains, it`s down about 20 percent from where it was trading in the middle of that month. Amgen said marketing approval for Aranesp, the company`s new version of its blockbuster drug Epogen, is taking longer than expected. The company did not say why. Epogen, which is used to treat anemia in kidney dialysis patients, had sales last year of $1.96 billion. Amgen also said that it now sees the dialysis patient population growing by 5 percent to 6 percent in 2001. That is lower than an original forecast of about 7 percent to 8 percent, said Elise Wang, an analyst at Salomon Smith Barney. As a result, Amgen now sees sales of Epogen and Aranesp, when approved, slowing to the "low teens" from an earlier forecast of "the high-teens to low 20s." Amgen said it now sees 2001 sales of Aranesp in new markets of between $100 million and $150 million, down from about $150 million to $200 million, Wang said. Amgen also said it expects 2001 earnings to grow in the low-double digits, down from an earlier forecast of an earnings increase in the "mid-teens." Amgen also said it doesn`t expect to receive marketing approval for its prostate cancer treatment Abarelix, which it`s developing with PRAECIS Pharmaceuticals (PRCS: news, msgs, alerts) , until the end of the year. Wang said the approval was originally expected in mid-2000. Amgen did not specify the reason for the delay in approving the drug, which had been given priority review status by the FDA. Amgen said it`s discussing the language to be contained on Aranesp`s label with the FDA, and that it believes it`s close to getting approval in the U.S. Legg Mason Wood Walker analyst Stefan Loren said the quarterly report was a "mixed bag." Sales of Epogen and Neupogen were disappointing, he said, but cost savings and other measures yielded bottom line numbers that were in line with his estimates, the analyst said. First quarter Epogen sales rose 14 percent to $503 million from $440 million. Amgen said sales of Neupogen, which is used to lower the risk of infection during cancer chemotherapy treatment, rose 18 percent to $294 million from $250 million in the same quarter last year. Loren also said that the delay in marketing approval for new products is also frustrating, but Amgen`s full pipeline and the likelihood that new drugs will be launched in coming months are positive for investors. Stephanie O`Brien is a reporter for CBS.MarketWatch.com. grüße, az-maja |
|
| aus der Diskussion: | "Ventro, Umsätze enorm, unser kl. Zockertreff, Part 3" |
| Autor (Datum des Eintrages): | az-maja (04.06.01 09:30:06) |
| Beitrag: | 120 von 1,000 (ID:3657479) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |